Retatrutide, a novel dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) receptor , is showing promising results in initial patient trials . Recent research https://orangebookmarks.com/story21427343/retatrutide-emerging-research-and-potential-medical-roles